Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

Open access
Du, Yi, Yamaguchi, Hirohito, Wei, Yongkun, Hsu, Jennifer L, Wang, Hung-Ling, Hsu, Yi-Hsin, Lin, Wan-Chi, Yu, Wen-Hsuan, Leonard, Paul G, Lee, Gilbert R, Chen, Mei-Kuang, Nakai, Katsuya, Hsu, Ming-Chuan, Chen, Chun-Te, Sun, Ye, Wu, Yun, Chang, Wei-Chao, Huang, Wen-Chien, Liu, Chien-Liang, Chang, Yuan-Ching, Chen, Chung-Hsuan, Park, Morag, Jones, Philip, Hortobagyi, Gabriel N, Hung, Mien-Chie·2016·Nature Medicine

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials. One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently approved by the FDA to treat ovarian cancer with mutations in BRCA genes. BRCA1 and BRCA2 have essential roles in repairing DNA double-strand breaks, and a deficiency of BRCA proteins sensitizes cancer cells to PARP inhibition. Here we show that the receptor tyrosine kinase c-Met associates with and phosphorylates PARP1 at Tyr907 (PARP1 pTyr907 or pY907). PARP1 pY907 increases PARP1 enzymatic activity and reduces binding to a PARP inhibitor, thereby rendering cancer cells resistant to PARP inhibition. The combination of c-Met and PARP1 inhibitors synergized to suppress the growth of breast cancer cells in vitro and xenograft tumor models, and we observed similar synergistic effects in a lung cancer xenograft tumor model. These results suggest that the abundance of PARP1 pY907 may predict tumor resistance to PARP inhibitors, and that treatment with a combination of c-Met and PARP inhibitors may benefit patients whose tumors show high c-Met expression and who do not respond to PARP inhibition alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.4032

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 243

Metadata

Authors
Du, Y., Yamaguchi, H., Wei, Y., Hsu, J. L., Wang, H.-L., Hsu, Y.-H., Lin, W.-C., Yu, W.-H., Leonard, P. G., Lee, G. R., Chen, M.-K., Nakai, K., Hsu, M.-C., Chen, C.-T., Sun, Y., Wu, Y., Chang, W.-C., Huang, W.-C., Liu, C.-L., Chang, Y.-C., Chen, C.-H., Park, M., Jones, P., Hortobagyi, G. N., & Hung, M.-C.
Venue
Nature Medicine
Published
2016-01-18
Volume
22
Issue
2
Pages
194-201
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2270704840
Cited by
243
References
8
FWCI
11.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. https://app.cochat.ai/papers/10.1038/nm.4032
The paper
Du, Y., Yamaguchi, H., Wei, Y., Hsu, J. L., Wang, H.-L., Hsu, Y.-H., Lin, W.-C., Yu, W.-H., Leonard, P. G., Lee, G. R., Chen, M.-K., Nakai, K., Hsu, M.-C., Chen, C.-T., Sun, Y., Wu, Y., Chang, W.-C., Huang, W.-C., Liu, C.-L., . . . Hung, M.-C. (2016). Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nature Medicine. https://doi.org/10.1038/nm.4032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.